Aktis Oncology Q1 2026 Earnings Report

Aktis Oncology EPS Results

• Actual EPS: -$0.38
• Consensus EPS: -$0.37
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Aktis Oncology Revenue Results

• Actual Revenue: $3.23 million
• Expected Revenue: $2.23 million
• Beat/Miss: Beat by +$997.00 thousand
• YoY Revenue Growth: N/A

Aktis Oncology Announcement Details

• Quarter: Q1 2026
• Date: 5/11/2026
• Time: Before Market Opens
• Conference Call Date: Monday, May 11, 2026
• Conference Call Time: 4:00PM ET

Aktis Oncology (NASDAQ:AKTS) (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. Aktis engages in translational research to move promising molecules from discovery into human testing, and may pursue collaborations or other corporate-development strategies common in the biopharmaceutical sector to accelerate program advancement and broaden development capabilities.

As a publicly traded company on the Nasdaq, Aktis Oncology operates within the broader biotech and pharmaceutical ecosystem and reports progress on its programs to investors and other stakeholders. Public disclosures and regulatory filings are the primary sources for up-to-date information on the company’s pipeline, development timelines and corporate plans. I couldn't find sufficiently detailed, independently verifiable public information on specific products, leadership or geographic headquarters to include here without risking inaccuracy.